This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

VIVO Clinical Study

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Cook Identifier:
First received: October 22, 2013
Last updated: February 13, 2017
Last verified: February 2017
The purpose of the VIVO Clinical Study is to evaluate the safety and effectiveness of the Zilver® Vena™ Venous Stent in the treatment of symptomatic iliofemoral venous outflow obstruction.

Condition Intervention
Symptomatic Venous Outflow Obstruction in the Iliofemoral Vein Device: Zilver Vena Venous Stent

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Evaluation of the Zilver® Vena™ Venous Stent in the Treatment of Symptomatic Iliofemoral Venous Outflow Obstruction

Further study details as provided by Cook:

Primary Outcome Measures:
  • Freedom from major adverse events [ Time Frame: 30 days ]
  • Primary patency [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • Change in VCSS [ Time Frame: 1 month ]
  • Change in VCSS [ Time Frame: 12 months ]

Enrollment: 243
Study Start Date: October 2013
Estimated Study Completion Date: November 2019
Estimated Primary Completion Date: November 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Zilver Vena Venous Stent Device: Zilver Vena Venous Stent
Other Name: venous stent


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • symptomatic venous outflow obstruction in one iliofemoral venous segment (i.e., one limb) per patient, demonstrated by:

    • CEAP "C" ≥ 3, or
    • VCSS pain score ≥ 2

Exclusion Criteria:

  • < 18 years of age;
  • pregnant or planning to become pregnant in the next 12 months;
  • planned surgical or interventional procedures of the target limb (except thrombolysis and/or thrombectomy in preparation for the procedure or vena cava filter placement prior to stent implantation in patients at high risk for pulmonary embolism) within 30 days prior to or any time after the study procedure;
  • planned surgical or interventional procedures for other medical conditions (i.e., not associated with the target limb) within 30 days prior to or after the study procedure;
  • lesions with intended treatment lengths extending into the inferior vena cava or below the level of the lesser trochanter;
  • lesion with malignant obstruction;
  • previous stenting of the target vessel;
  • iliofemoral venous segment unsuitable for treatment with available sizes of study devices.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01970007

  Show 30 Study Locations
Sponsors and Collaborators
Principal Investigator: Anthony J. Comerota, MD, FACS, FACC Jobst Vascular Institute
Principal Investigator: Lawrence "Rusty" Hofmann, MD Stanford University
  More Information

Responsible Party: Cook Identifier: NCT01970007     History of Changes
Other Study ID Numbers: 11-010
Study First Received: October 22, 2013
Last Updated: February 13, 2017

Keywords provided by Cook:
outflow obstruction
iliofemoral vein processed this record on June 23, 2017